Clinical Edge Journal Scan

Brexucabtagene autoleucel shows promise in relapsed or refractory mantle cell lymphoma in routine practice


 

Key clinical point: Brexucabtagene autoleucel (brexu-cel) demonstrated promising efficacy and a favorable safety profile in patients with relapsed or refractory mantle cell lymphoma (MCL) in real-world practice, which is consistent with that reported in the ZUMA-2 trial.

Major finding : At a median follow-up of 14.3 months after infusion , the best overall and complete response rates were 90% and 82%, respectively. The 6- and 12-month progression-free survival rates were 69% (95% CI 61%-75%) and 59% (95% CI 51%-66%), respectively. The grade ≥3 cytokine release syndrome and neurotoxicity rates were 8% and 32%, respectively.

Study details: This multicenter retrospective study included 189 patients with relapsed or refractory MCL who underwent leukapheresis for commercial manufacturing of brexu-cel, of which 168 received brexu-cel infusion.

Disclosures: This study was sponsored by a US National Cancer Institute cancer support grant. Some authors reported ties with various organizations.

Source: Wang Y et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: Results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023 (Feb 8). Doi: 10.1200/JCO.22.01797

Recommended Reading

Bendamustine-rituximab effective in elderly with indolent non-Hodgkin's or mantle cell lymphoma
B-Cell Lymphoma ICYMI
Mantle cell lymphoma: Real-world benefits of rituximab maintenance after first-line BR/R-CHOP
B-Cell Lymphoma ICYMI
Second-line lisocabtagene maraleucel shows promise in large B-cell lymphoma
B-Cell Lymphoma ICYMI
Relapsed follicular lymphoma: Autologous stem cell transplantation shows long-term curative effects
B-Cell Lymphoma ICYMI
Ibrutinib shows long-term benefits in chronic lymphocytic leukemia/small lymphocytic lymphoma in RESONATE-2
B-Cell Lymphoma ICYMI
Diffuse large B-cell lymphoma: No impact of lenalidomide after R-CHOP on unfavorable prognosis of low NK-cell counts
B-Cell Lymphoma ICYMI
Diagnosis to treatment interval: A crucial prognostic factor in newly diagnosed mantle cell lymphoma
B-Cell Lymphoma ICYMI
Commentary: New treatment strategies for diffuse large B-cell lymphoma, March 2023
B-Cell Lymphoma ICYMI
CLL treatment: More infections among real-world patients
B-Cell Lymphoma ICYMI
CLL and surgery are more compatible than ever
B-Cell Lymphoma ICYMI